Abstract:Background: Studying protein expression involved in cancer from patient-derived xenografts (PDX) enhances understanding of tumorigenesis and may shed light on patient therapeutic decisions. Recently, mass spectrometry-based proteomics sequencing techniques have enabled the acquisition of high-throughput PDX protein/phosphoprotein expression profiles and paved a way for investigating oncogenic signaling pathways and their interactions in different tumor histologies. Integrated analysis of these proteomic data with existing biomarkers derived from whole exome and RNAseq data will provide the community with a rich resource for translational research. Materials and methods: iTRAQ-based proteomics/phospho-proteomics data, with 11 Tandem Mass Tag (TMT) channels, were processed and median-normalized at gene level. The gene expression data were derived from tximport and DESeq2 from of RNA-Seq. In addition, whole exome sequencing (WES) data were used to compute mutations and copy number profiles. For data visualization, the R Bioconductor package ComplexHeatmap was used extensively. Results: PDX proteomics/phospho-proteomics data were analyzed alongside with gene expression, copy number and mutational profiles for several cancer types, revealing vivid molecular regulation for many cancer-related pathways. A moderate yet significant Spearman correlation coefficient of over 0.45 and 0.5 was observed between proteomics and RNA-Seq data at gene and pathway level, respectively. The PDX protein and gene expression pattern from common cancer regulatory pathways of bladder (BLCA, n=32 models), colon (COAD, n=82), lung (NSCLC, n=32), pancreatic (PAAD, n=52), metastatic breast cancer (CSNOS) (n=16) and other histologies were aggregated and discussed at the model level. EGFR, MET and cell-cycle genes CDKN2A and CDKN2B exhibited significant positive correlation among copy number, gene expression and protein expression profiles. Protein and gene expression profiles of PAM50 genes were shown for CSNOS samples, to further sub-classify or correct misclassification. Further analysis using proteomics/phospho-proteomics data with CNA identified several trans-regulatory events. Lastly, we identified RTN1 as a potential biomarker, exhibiting lower expression in sensitive rare-tumor PDX models prior to Axitinib and Vandetanib treatment. Conclusions: With the multi-omics datasets comprising proteomics/phospho-proteomics, RNA-Seq and WES datasets from the NCI Patient Derived Models Repository cohort, we were able to query some important cancer biological processes at a higher resolution. In addition, we revealed gene- and pathway-level regulatory differences from various histologies. Overall, the multi-omics data from PDX models showed promising recapitulation of original tumor activity and should continue to serve as an amenable and scalable drug screening platform for pre-clinical trials. Citation Format: Peter I. Wu, Li Chen, Yuri Kotliarov, Jianwen Fang, Yingdong Zhao, Yvonne Evrard, Lijun Chen, Shahanawaz Jiwani, Biswajit Das, Chris A. Karlovich, Hui Zhang, Lisa McShane, Melinda G. Hollingshead, Mickey Williams, James H. Doroshow. Integrated proteogenomic analysis for the NCI patient-derived cancer model repository [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6915.

Supplementary Data File 6 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 5 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 3 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 4 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 1 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Figures and Tables from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 2 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Igmdr: Integrated Pharmacogenetic Resource Guide to Cancer Therapy and Research.

Additional File 2: of Integrative Omics Analyses Broaden Treatment Targets in Human Cancer

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Abstract 6915: Integrated proteogenomic analysis for the NCI patient-derived cancer model repository

Abstract 3549: PMed-TRIAL PDX database: Integrated multidimensional information to facilitate new drug development

Additional File 2 of A Novel Patient-Derived Organoids-Based Xenografts Model for Preclinical Drug Response Testing in Patients with Colorectal Liver Metastases

Supplementary Data from Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer

Supplementary Figure S5 from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies

Integrative molecular analyses of the MD Anderson prostate cancer patient-derived xenograft (MDA PCa PDX) series

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations

Supplementary Figure 3 from Systems Analysis of the NCI-60 Cancer Cell Lines by Alignment of Protein Pathway Activation Modules with “-OMIC” Data Fields and Therapeutic Response Signatures

Figure S4 from Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models

Additional File 6: Table S2. of Cogena, a Novel Tool for Co-Expressed Gene-Set Enrichment Analysis, Applied to Drug Repositioning and Drug Mode of Action Discovery